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ABSTRACT 
Multiprotein complexes regulate most if not all cellular functions. Elucidating the structure 
and function of these complex cellular machines is essential to understanding biology. 
Moreover, multiprotein complexes by themselves constitute powerful reagents as biologics 
for the prevention and treatment of human diseases.  Recombinant production by the 
baculovirus / insect cell expression system is particularly useful for expressing proteins of 
eukaryotic origin and their complexes. MultiBac, an advanced baculovirus / insect cell 
system has been widely adopted in the last decade to produce multiprotein complexes with 
many subunits that were hitherto inaccessible, for academic and industrial research and 
development. The MultiBac system, its development and numerous applications are 
presented. Future opportunities for utilizing MultiBac to catalyze discovery are outlined.    
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1/ Introduction –The baculovirus expression vector system (BEVS) 
More than 30 years ago, the high level production of a heterologous protein by using an 
insect specific baculovirus, derived from the Autographa californica multiple nuclear 
oolyhedrosis virus (AcMNPV) was reported. Max Summers and co-workers produced 
functional human IFN- in insect cells infected by a recombinant baculovirus [1]. This 
development was made possible by the previous observations that late in its viral life cycle, 
baculovirus expresses at very high levels a protein, polyhedrin, which is not essential in 
laboratory culture. Substitution of the polyhedrin gene in the baculoviral polh locus by a 
foreign gene of interest resulted in comparably high-level expression of the desired gene 
product, driven by the polh promoter, without compromising virus infectivity and the viral 
life cycle [2]. Shortly after, a second study by Lois Miller and colleagues demonstrated that 
another very late promoter p10, showed similar characteristics and could also be used for 
high-level production of heterologous proteins [3].  
These two seminal studies established the baculovirus / insect cell expression system 
as a powerful means to produce proteins recombinantly. In the three decades since these 
hallmark contributions, baculovirus expression has become a widely adopted technology for 
academic and  industrial applications, in research and development as well as manufacturing, 
and a wide range of proteins have been made by baculovirus expression vector systems 
(BEVS) [2, 4-7]. Multicomponent virus like particles (VLPs) resembling complex virus 
shells, have been produced successfully with BEVS, including VLPs from bluetongue,  
rotavirus and others [8-11]. More recently, the first baculovirus produced proteins have been 
approved in the therapy or prevention of human disease, including vaccines against influenza 
(Flublok®) and cervical cancer (Cervarix®), and immune-therapeutics against tumors of the 
prostate (Provenge®) [4]. Moreover, baculovirus itself has emerged as a versatile tool for 
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gene therapy, either as a production system for recombinant adeno-associated viruses [12-14] 
or as a DNA-based gene delivery vehicle in its own right [15,16].  
The development of BEVS for heterologous protein production and its manifold 
exploits have been authoritatively reviewed recently in a number of contributions, 
recapitulating comprehensively the technical aspects of this technology [2, 4, 5]. The subject 
of this present contribution is MultiBac, a particular baculovirus expression vector system 
developed and implemented more recently [17-25]. MultiBac was originally conceived to 
meet the imposing challenge of producing eukaryotic multiprotein complexes, vital 
cornerstones of biological activity, in high quality and quantity for high-resolution structural 
and functional analysis. The system has been uniquely successful in catalyzing multiprotein 
complex research globally. MultiBac, its ongoing development, its numerous applications 
and future prospects are reviewed in the following.  
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2/ The MultiBac system for expressing eukaryotic multiprotein complexes 
Protein complexes catalyze key functions in the cell, and as a consequence, are an intense 
focus of contemporary biological research efforts. Genomics and proteomics studies have 
underpinned that most if not all proteins in eukaryotic cells are parts of larger assemblies, 
with in humans often comprise ten or more individual subunits. The complex interplay of 
proteins in these complexes is essential for maintaining cell homeostasis and biological 
activity, and for development. High-resolution functional and structural characterization of 
the large number of multiprotein assemblies in the cell is critical to understanding cell 
biology [20, 26, 27]. 
 Multisubunit complexes may be purified from their native cell environment and their 
structure and function analyzed successfully at near-atomic resolution, provided they are 
sufficiently abundant and homogeneous. Well-known examples include RNA polymerases 
and ribosomes [28-31].  The overwhelming majority of multiprotein complexes in the cell, 
however, are characterized by low or very low abundance, which considerably complicates or 
even rules out their purification from native source material. Furthermore, it is becoming 
increasingly clear that many proteins may exist not only in one, but a number of distinct 
complexes, carrying out diverse functions depending on the partner molecules they associate 
with at a given time. Together, this often obstructs obtaining compositionally pure and 
homogenous material by classical fractionation of cells and subsequent biochemical 
purification, notwithstanding significant progress notably in endogenous tagging methods to 
genomically modify endogenous proteins by powerful extraction aids such as tandem affinity 
purification (TAP) tags, for instance [32-34]. A solution to these issues is recombinant 
overproduction, enabled by the development and implementation of powerful overexpression 
technologies that can achieve high level production of homogeneous and active eukaryotic 
complexes for detailed mechanistic analysis at the molecular level. 
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 Recombinant protein overproduction had a profound and game-changing impact on 
protein science, making previously inaccessible targets readily available. A very large 
number of proteins, their mutants and variants have been produced recombinantly, and their 
structure and function determined at high resolution. The availability of entire genomes has 
made it possible to address the protein repertoire of cells on a systems-wide scale, applying 
high-throughput technologies [35]. Recombinant protein expression in E.coli as a prokaryotic 
expression host has become commonplace in molecular biology laboratories world-wide.  
The recombinant production of protein complexes of eukaryotic origin, however, poses a 
number of challenges which frequently rule out prokaryotic expression hosts. Eukaryotic 
proteins are often large and can exceed the size range E.coli can overproduce efficiently 
(typically up to ~100kDa). Post-translational modifications and processing are commonplace 
in eukaryotic proteins and can be essential for activity, but are generally not supported by a 
prokaryotic host. The eukaryotic protein folding machinery differs significantly from the 
chaperone system in E.coli, further restricting its utility for eukaryotic protein production. 
Much effort has been and is being devoted to improving prokaryotic host systems for 
heterologous production [36-38]. However, in many cases eukaryotic proteins and their 
complexes will likely require a eukaryotic expression host system for their overproduction, 
and if a eukaryotic system can be applied with comparable ease as E.coli based expression, 
then this system will likely be a preferred choice. The MultiBac system has been developed 
precisely with this intention to put in place such a eukaryotic expression system that supports 
high-level and high-quality production of eukaryotic proteins and their complexes, by using 
standard operating protocols (SOPs) which make its application comparably facile and 
routine as E.coli-based expression [18, 39-41].   
 
 
 
7 
 
2.1/ MultiBac developments 
The baculovirus / insect cell expression system is particularly well-suited for the production 
of eukaryotic proteins. At the core of this expression technology is a recombinant baculovirus 
into which the heterologous genes of interest have been inserted. This composite baculovirus 
is then used to infect insect cell cultures grown in the laboratory. MultiBac is a more recent 
bacoluvirus / inscet cell system which has been specifically tailored for the overproduction of 
eukaryotic complexes that contain many subunits [40]. An important prerequisite for the 
efficient expression of eukaryotic proteins and their complexes are easy-to-use reagents for 
(multi)gene assembly and delivery. Equally required are robust and standardized protocols 
for all steps involved in the expression experiment, from gene to purified protein complex. 
These steps should ideally be implemented as standard operating procedures (SOPs), 
especially in laboratories where the expression experiment itself and its optimizations are not 
the primary objective, but rather the protein complex and the determination of its structure 
and mechanism within a reasonable time-frame. The implementation of such SOPs will then 
enable non-specialist users to apply the technology with relative ease. The MultiBac system 
has been designed to meet these requirements [18, 40, 41]. 
 MultiBac consists of an engineered baculovirus that has been optimized for 
multiprotein complex expression [17] (Fig. 1). The MultiBac baculovirus exists as a bacterial 
artificial chromosome (BAC) in E.coli cells (DH10MultiBac or DH10MB). The replicon (F-
factor) present on the BAC restricts its copy number to (typically) one [42]. The MultiBac 
genome has been modified by deleting proteolytic and apoptotic functionalities from the 
baculoviral genome that were found to be detrimental for the quality of the heterologous 
target complexes produced [17-19, 23, 41]. The MultiBac system furthermore comprises an 
array of small custom-designed DNA plasmid modules that facilitate the assembly of 
multigene expression cassettes and their integration into the baculoviral genome (Fig. 1). 
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Integration of the multigene expression cassette constructions into the baculoviral genome 
occurs via two sites (Fig. 1). One is a mini-Tn7 attachment site embedded in a lacZ gene 
that is used for blue/white selection and is accessed by the Tn7 transposase which is 
expressed in the DH10MB cells from a helper plasmid as described previously [43]. Upon 
integration into this Tn7 site, the LacZgene is disrupted; white colonies indicate successful 
transposition. A second entry site is formed by a short imperfect inverted repeat, LoxP, at a 
location distal from the Tn7 attachment site (Fig. 1). It can be accessed by means of the Cre 
enzyme, a site-specific recombinase that targets the LoxP imperfect inverted repeat (Fig. 1). 
Cre integration occurs by fusing LoxP sites present on the Multibac genome on the one hand, 
and on a DNA plasmid module on the other. Successful Tn7 and also Cre integration is 
imposed by antibiotic selection against the resistance markers encoded by the DNA plasmid 
modules integrated into the MultiBac genome. The integration sites can be used to integrate 
genes encoding for one or several multiprotein complexes of choice, but also for additional 
functionalities that may be required to activate or inactivate the complex (kinases, 
phosphatases, acetylases, deacetylases, others), support its folding (chaperones) or post-
translational processing such as glycosylation [19, 23, 44-46]. 
 The composite MultiBac baculoviral genome which contains all desired heterologous 
genes is then purified from small bacterial cultures using standard alkaline lysis protocols and 
applied to small insect cell cultures, typically in six-well plates, with a lipidic or non-lipidic 
transfection reagent [24, 41]. The resulting live baculovirions are harvested and applied to 
larger insect cell cultures for heterologous protein production and purification. Production 
baculovirus is then stored for example at 4⁰C in the dark to avoid degeneration of viral titers. 
A more secure long term storage method is provided by freezing small aliquots of 
baculovirus infected insect cells (BIICs) that are then stored in liquid nitrogen [47].  
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 A centerpiece of the MultiBac system is the facilitated assembly of genes into 
multiexpression cassettes (Fig. 1, 2). Originally, this was addressed by creating two different 
DNA plasmid modules that contained a so-called Multiplication Module. This module 
allowed iterative assembly of single or dual expression cassettes, each fitted with a promoter 
(p10 or polh) by restriction/ligation utilizing compatible sites that would be destroyed upon 
ligation [17]. One plasmid (pFBDM) accessed the Tn7 site, the second plasmid (pUCDM) 
accessed the LoxP site on the MultiBac genome. Both plasmids could be fitted with one to 
many foreign genes by means of multiplication. The pUCDM plasmid contains a conditional 
origin of replication derived from the phage R6K. Its survival therefore hinges on the 
presence of a particular gene (pir) in the genome of specific E.coli strains. If a pUCDM 
plasmid is transformed into DH10MB cells which are pir negative, it will only survive if it is 
productively fused to the MultiBac genome by Cre-LoxP reaction [17]. 
 The plasmid module repertoire of the MultiBac system was subsequently expanded by 
fitting out the pFBDM plasmid with a LoxP site, giving rise to pFL. A further plasmid was 
created, pKL, which in contrast to the high-copy number pFL plasmid is propagated at low 
copy numbers, and thus could accommodate difficult or very large genes that had turned out 
to be unstable in pFL. A new version of pUCDM was designed with a different resistance 
marker (spectinomycin), pSPL. pSPL or pUCDM could now be fused either with the 
MultiBac genome in DH10MB if Cre was expressed, or in vitro with pFL or pKL. All 
plasmids retained the Multiplication Module and therefore could be outfitted with several to 
many genes in an iterative way. pUCDM and pSPL were now denoted Donor plasmids (D), 
while pFL and pKL were denoted Acceptors (A) (Fig. 2) [18, 41]. One Acceptor could be 
fused with one or two Donors by Cre-LoxP reaction in vitro, and productive fusions were 
identified by the combination of resistance markers present on the fusion. The fused AD or 
ADD constructs carrying several to many heterologous genes, could then be inserted into the 
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Tn7 attachment site of the MultiBac genome by transposition in DH10MB cells as before. In 
vitro fusion of AD or ADD plasmids prior to integration into the Multibac genome did not 
rule out use of the LoxP site present on the viral backbone. Integration into the viral loxP site 
simply had to precede the transposition reaction [18]. 
  A sine qua non of contemporary structural biology is automation, to increase the 
through-put of expression experiments by robotic approaches. As a consequence, the 
multigene assembly technology of the MultiBac system was adapted to automation by using a 
liquid handling robot [24, 25]. For this, the tandem recombineering technology (TR) 
originally developed for prokaryotic complex expression [38] was adapted to the MultiBac 
system [48]. TR combines sequence-and-ligation independent gene insertion (SLIC) with 
Cre-LoxP fusion to generate multigene expression constructs in high-throughput in a robotic 
setup. Adaptation of the MultiBac plasmids to TR required subtle adjustments of the plasmids 
resulting in Acceptor plasmids pACEBac1 and pACEBac2 as well as Donor plasmids pIDK, 
pIDS and pIDC that are robotics-compatible [22, 24, 40]. Concomitantly, with the objective 
to simplify the monitoring of protein production by measuring fluorescence levels, a new 
baculovirus genome, EMBacY, was created expressing a fluorescent protein (YFP) from its 
backbone, with fluorescence intensity increasing concomitantly with the quantity of the 
heterologous protein complex expressed at the same time. All Acceptor and Donor plasmids 
developed for the MultiBac system over time are compatible with each other, and also with 
the MultiBac and EMBacY genomes (and other MultiBac genome derivatives) that were and 
are being developed (see also 2.3 and 2.4).  
 
2.2/ A MultiBac user access platform 
The MultiBac system rapidly developed into a sought after tool following its introduction and 
original publication, compellingly underscoring the current need for an accessible 
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multiprotein expression technology for eukaryotic multiprotein complexes. The number of 
laboratories using MultiBac approaches a thousand at the time this review is written. 
Research groups in academia, the biotech and pharma industries are implementing MultiBac 
to produce their specimens of interest. Moreover, biotech spin-offs were founded based on 
MultiBac developments, including a preclinical vaccine development company, Redvax 
GmbH, which in 2015 was acquired by the global pharma enterprise, Pfizer.  
The high demand for accessing this technology resulted in the establishment of a 
dedicated research and training platform at the European Molecular Biology Laboratory 
(EMBL) in the Eukaryotic Expression Facility (EEF) established at the EMBL Outstation in 
Grenoble (Fig. 3). The EEF has been supported since 2008 by the European Commission 
(EC) through infrastructure grants (P-CUBE, BioStruct-X, INSTRUCT) and by the national 
(French) research agency (ANR) through the Investissement d’Avenir program. More than a 
hundred projects per year, by local national and transnational users, including academic 
research projects as well as industrial contracts have been processed in the facility, covering a 
wide range of applications in basic and applied research and development. Academic project 
access is based on the sole criteria of excellence, determined by an independent panel 
reviewing research proposals. The facility has implemented a SOP-based procedure for 
routinely and rapidly moving projects through the MultiBac platform pipeline [23, 24].  
The entire process from preparing the multigene expression construct to (small-scale) 
purification of the specimens of interest requires around two weeks according to this 
protocol. A large number of constructs can be processed in parallel according to this protocol. 
Virus amplification as well as heterologous protein production is monitored by measuring the 
signal of yellow fluorescent protein (YFP) in small (1 million cells) aliquots withdrawn from 
the cell cultures at defined intervals. The YFP signal reaching a plateau indicates maximal 
production of the desired complex specimen and the expression cultured is harvested at this 
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point for further processing and purification. Particular care is taken to assure highest quality 
virus production during virus amplification – early (budded) virus is harvested throughout the 
amplification process to avoid accumulation of defective viral particles that would 
compromise virus performance. Initial virus is stored at 4°C, while production virus is stored 
as BIICs in liquid nitrogen [21-24] (Fig. 3).  
 
2.3/ OmniBac: Universal multigene transfer vectors 
Two approaches for foreign gene integration into the baculoviral genome dominate the field. 
One approach depends on the baculoviral genome present as a BAC in E.coli cells, and relies 
on gene integration by transposition catalyzed by the Tn7 transposase which is constitutively 
expressed from a dedicated (helper) plasmid in the cells harboring the BAC. The foreign 
genes are provided by transforming a transfer plasmid into these E.coli cells. Selection for 
recombinant virus occurs based on the resistance marker that is present on the transfer 
plasmid and also integrates into the BAC that is the baculoviral genome, and blue / white 
selection – productive transposase mediated integration destroys a lacZ gene. The MultiBac 
system applies this strategy, extended by the option to provide in addition to the Tn7 
transposase also the site-specific Cre recombinase from a second dedicated helper plasmid, to 
fuse an additional plasmid into a LoxP site present on the MultiBac baculoviral genome [17, 
40, 41].  
 The alternative, original approach is based on homologous recombination, mediated 
by DNA regions in the transfer plasmid that are also present in the baculoviral genome, 
flanking the polh locus that had been inactivated by destruction of the polh gene. These 
regions of homology correspond to the open reading frames Orf1620 and lef2/603. By using 
this method, insertion occurs by co-transfecting the transfer plasmid and the purified 
baculoviral genome into insect cells. The baculoviral genome is typically linearized in the 
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region between Orf1629 and lef2/603, to suppress formation of virus devoid of the 
heterologous DNA of interest. Fusion of the plasmid DNA with the baculoviral DNA to 
create a replicating genome is then achieved via the homologous recombination system of the 
insect cells. The genome is thus re-circularized, concomitantly inserting the gene of interest. 
Live virions are then produced that express the desired protein(s). 
Both methods have advantages and disadvantages. The Tn7/BAC based integration 
approach is the method of choice in many laboratories, mainly due to its simplicity. Since the 
baculoviral genome exists as a BAC in E.coli, it can be, in theory, propagated indefinitely 
and used for many experiments after obtaining the initial aliquot. Moreover, it can also be 
manipulated by gene editing technologies in its E.coli host cell. In contrast, the linearized 
baculoviral DNA for homologous recombination has to be obtained from the supplier for 
every experiment de novo and cannot be propagated at will. Furthermore, the homologous 
recombination method is arguably somewhat more involved and may require specialist 
knowledge. On the other hand, this approach is more amenable to automation as compared to 
the BAC-based method which is characterized by many steps some of which (such as blue / 
white screening) cannot be readily scripted into robotics routines. A further disadvantage of 
the BAC-based system may be found in the relative instability that was found for BAC-
derived baculoviruses in insect cells, presumably originating from the presence of extended 
bacterial DNA elements (selection marker, F-replicon, LacZ gene) [4, 49], limiting its use 
in human applications mainly to preclinical studies [4]. In fact, baculoviruses used in 
commercial production to date are still being made almost exclusively by applying the 
classical homologous recombination technique [4]. 
Available BEVS all relied on either one method or the other, which were mutually 
exclusive, and the choice of the transfer plasmid decided which virus would be used for 
protein production. This situation is unsatisfactory given that both systems (BAC/Tn7-based 
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and classical) provide unique opportunities. Moreover, numerous baculoviruses with 
customized functionalities have been created for both applications, each with its own merit. 
We therefore designed and created the “OmniBac” transfer plasmids which combine the 
DNA elements required for Tn7 transposition in the BAC-based system and also the 
homology regions for baculovirus generation following the classical method, and thereby are 
universally applicable (Fig. 4). These OmniBac transfer plasmids function as Acceptors in the 
MultiBac system (Fig. 4). They can be combined with a variety of Donors to yield multigene 
Acceptor-Donor fusions that can then be funneled into any baculovirus of choice [50].  
 
2.4/ The ComplexLink polyprotein technology 
A challenge frequently encountered when overexpressing protein complexes relates to 
unbalanced expression levels of the individual protein subunits that are to assemble into the 
biological target superstructure. If a particular subunit is badly made in a co-expression 
experiment, it will limit the overall yield of the fully assembled protein complex 
dramatically. This challenge can be addressed within limits by co-infection approaches using 
several viruses, or the choice of promoters. In contrast to very late promoters such as polh 
and p10, earlier promoters are expressed at lower levels. However, it may be often 
impractical to resort to co-infection or to tuning protein expression levels by promoter choice, 
also due to the fact that the timing of the production of protein subunits will then be altered as 
well, with often unpredictable consequences. A solution to such problems can derive from 
observing the strategies certain viruses utilize to realize their proteome. Coronavirus, the 
agent that causes severe acute respiratory syndrome (SARS), produces its complete proteome 
from two long open reading frames (ORFs) that give rise to polyproteins in which the 
individual protein specimens are covalently linked. A highly specific protease, also encoded 
by the ORF, then liberates the individual proteins by cleaving them apart. 
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 The ComplexLink technology implements this strategy for recombinant polyprotein 
production from polygenes [22, 40, 51] (Fig. 5). In ComplexLink, genes encoding for a 
protein complex of choice are conjoined to yield a single ORF. This ORF gives rise to a 
polyprotein in which the individual proteins are linked by short amino acid sequences 
representing a cleavage site for the NIa protease from tobacco etch virus (TEV) which is also 
encoded by the ORF and is the first protein produced. In addition, a cyan fluorescent marker 
protein (CFP) is present at the C-terminal end of the polyprotein construction. Upon 
translation. TEV protease liberates itself, and all other proteins including CFP by cleaving the 
TEV-specific proteolytic sites. The ComplexLink plasmids, pPBac, pKL-PBac and pOmni-
PBac function as Acceptors in the MultiBac system and can be fused to Donors which may 
contain further genes encoding for polyproteins. The ComplexLink technology proved to be 
highly successful in producing difficult-to-express protein complexes in high quality and 
quantity, including the physiological core complex of human general transcription factor 
TFIID [52-54]. A notable exploit is influenza polymerase, an important drug target to combat 
the flu, which has remained inaccessible for 40 years since its discovery. Influenza 
polymerase has been produced, for the first time, successfully using ComplexLink in 
conjunction with MultiBac, enabling elucidation of its structure and mechanism by X-ray 
crystallography at near-atomic resolution [55, 56] (Figs. 5, 6). 
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3/ Applications 
The MultiBac system in its original form was introduced in 2004, and has become the method 
of choice for a wide range of applications. Primarily developed for accelerating structural 
biology of multiprotein complexes, it has since then been modified and improved to benefit 
also other fields, in basic and applied research. We have followed these developments with 
interest and have occasionally highlighted them in invited review articles and commentaries 
[40, 53, 57, 58]. In the following, we intend to summarize these developments without being 
exhaustive, focusing on recent exploits by researchers who adopted the system we had 
developed, to catalyze their research.  
3.1/ Accelerating complex structural biology 
The first community which implemented MultiBac were structural biologists interested in 
elucidating the architecture and mechanics of important multiprotein machines in cell biology 
at the molecular, near-atomic level. This is also the field were an impressive flurry of highest 
impact MultiBac-enabled contributions was achieved to date. We had highlighted some of 
these exciting structures, including important drug targets such as the LKB1-STRAD-MO25 
complex [59], and the first structure of a nucleosome-bound chromatin remodeler, Isw1 [60] 
in a contribution just over two years ago in Trends in Biochemical Sciences [40]. In the short 
time since then, spanning a mere two years, a large number of new structural studies have 
been carried out using material produced with MultiBac. A selection of these exploits is 
presented in Figure 6.  
 Landmark achievements are the recent crystal structures of influenza polymerase [55, 
56]. This success was catalyzed by applying the ComplexLink and MultiBac technologies 
together, to produce this trimeric protein complex which had remained elusive for decades. 
The structures describe fluA and fluB variants of the polymerase bound to its RNA ligand, 
and provide important structural insights into cap-snatching and RNA synthesis by this 
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enzyme complex, opening up new avenues for pharmaceutical development to combat flu.  
Further crystallographic exploits include the structures of human cytoplasmic dynein-2 
primed for its power stroke [61], the human argonaute-2 / RNA complex [62], the structure of 
the spliceosomal protein Prp8 bound to and RNA helicase, Brr2 [63, 64], structures of 
PI4KIIIkinase complexes [65] among numerous others. Highlights achieved by using 
MultiBac produced material for electron microscopic studies include the structures of COP1-
coated vesicles, revealing alternate coatomer conformations and interactions [66,67], the 
architecture of the physiological core of human general transcription factor TFIID [52, 58], or 
the elucidation of the molecular mechanisms of the anaphase promoting complex APC/C at 
sub-nanometer resolution [68]. Recently, the entire human Mediator transcription factor holo-
complex has been successfully assembled by using MultiBac, and functionally characterized 
[69]. MultiBac reagents have been incorporated into pipelines for producing membrane 
proteins and their complexes [70]. We anticipate that many more exciting structures of 
important protein assemblies will be determined in the future, by using the MultiBac system 
as a production tool. 
 
3.2/ MultiBac in pharma and biotech 
The baculovirus / insect cell system has had a major impact on the production of high-value 
pharmacological targets, for pharmaceutical characterization, structure-based drug design, 
diagnostics, biosensor engineering and high-throughput proteomics [2, 4, 5, 71]. Notably 
human proteins, virus-like particles and vaccines have been successfully expressed by BEVS 
[2, 4, 5]. Glycoproteins are sought-after biologics in the pharma and biotech sector, and insect 
cells have proven to be well suited for the expression of biologically active and immunogenic 
specimens. The MultiBac system has been engineered to enable high-quality production of 
glycoproteins and their complexes. The original MultiBac baculoviral genome was already 
lacking the v-cath and chiA genes, which are encoding for a cathepsin-like protease and 
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chitinase, respectively. Both v-cath and chiA have been shown to be detrimental to 
glycoprotein production [72-74]. The glycosylation pattern of secreted proteins in insect cells 
differs from mammalian patterns which involve more complex N-glycans [75, 76]. These 
differences can have detrimental effects on human glycoproteins produced in insect cells. To 
overcome this impediment, a new MultiBac-derived baculovirus, SweetBac, was constructed, 
which includes glcosylases in the backbone, resulting in mammalianized glycosylation 
patterns of SweetBac produced glycoproteins [23, 44, 45]. More recently, improved MultiBac 
variants were introduced to minimize fucosylation in insect cell derived glycoproteins to 
reduce binding to antibodies from the sera of patients with allergies [46]. 
 The baculovirus / insect cell system has demonstrated its aptitude to produce complex 
multicomponent assemblies such as virus-like particles (VLPs) [4, 9-11, 77]. VLPs are 
promising candidates for vaccination. VLPs resemble natural virus shells, but are lacking 
genetic material and therefore are safe and not infectious. VLPs can be proteinaceous, such as 
for example papilloma VLPs used to prevent cervical cancer. More recently, enveloped 
viruses have been successfully produced using BEVS, including influenza and chikungunya 
vaccine candidates [4, 77-80]. The MultiBac system was already successfully used to produce 
a number of VLPs including an array of papilloma serotypes [40]. Complex VLPs 
representing highly pathological virus strains were produced safely by MultiBac [81]. In 
particular the availability of OmniBac plasmids, which are part of the MultiBac vector suite, 
may provide unique opportunities for VLP vaccine development, as they are and are equally 
useful for exploratory preclinical studies in high-throughput as well as pharmacological 
production by choosing the most appropriate viral backbone for large scale expression. 
 Baculoviruses not only infect insect cells, but can also transduce mammalian cells 
efficiently [15, 82-84]. By choosing mammalian-active promoters instead of polh, p10 or 
other baculoviral promoters, proteins of interest can be produced from a baculovirus that has 
19 
 
entered a mammalian host cell. Baculoviruses do not replicate in mammalian cells, therefore, 
the current consensus is that this BacMam approach can be performed safely in laboratories. 
A particular benefit BacMam is that large DNA insertions including multicomponent 
signaling cascades or entire metabolic pathways can be transduced into mammalian cells 
efficiently by the baculovirus which can tolerate very large gene insertions, and can be 
amplified and produced in large amount in a straight-forward way in insect cell cultures. 
Baculovirus is thus emerging as a highly promising gene delivery tool into mammalian cells, 
for a multitude of applications [14, 15]. In this context, multigene MultiBac constructions 
were successfully used to produce recombinant adeno-associated viruses (AAVs) for gene 
therapy [12, 13, 40]. 
 
3.3/ Synthetic Biology: Rewiring the genome 
The AcMNPV genome has a size of around 130 kilobases and contains many functionalities 
which are essential in the natural life cycle of the virus, but dispensable in laboratory culture. 
Moreover, in the laboratory, it has been recognized that the genome has a tendency to 
undergo multiple deletions in its genome during amplifications, notably in regions containing 
foreign gene cargo that has been inserted for overproduction [4, 50]. This can have severely 
detrimental consequences for heterologous target protein production, especially for 
fermenter-scale expression of biologics which require large foreign DNA insertions in the 
viral genome, and several rounds of amplification until sufficient volumes of production virus 
are obtained to charge the fermenter. We have shown that some of these limitations can be 
overcome at least on laboratory-scale by stringently adhering to virus generation protocols 
that avoid or limit the occurrence of widespread deletions [18]. Moreover, it appears that 
there is considerable scope for improving virus performance by eliminating mutational or 
deletion hot-spots in the viral genome, and by removing DNA regions which are not required 
in cell culture. The baculoviral genome, in particular when present as a BAC, lends itself 
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excellently to genome manipulation and editing techniques. We and other have exploited this 
to remove unnecessary or undesired functionalities from the virus, such as the polh, p10, v-
cath and chiA genes.  
The advent of efficient synthetic biology techniques now holds the promise to reverse 
this somewhat cumbersome top-down approach, and to rationally redesign and rewire the 
baculoviral genome bottom-up by applying DNA synthesis and assembly methods that have 
become available more recently. Interestingly, comparison of baculovirus sequences in 
genome databases indicated that most genes and DNA elements thought to be required for 
survival of the virus in cell culture are confined to roughly one half of the circular viral 
genome, while the other half contains DNAs that can be probably disposed of in the 
laboratory [50]. This approach may hold challenges given the complex interplay of 
baculoviral proteins and their relative expression levels during the different phases of the 
viral life cycle [4]. Notwithstanding, synthetic approaches, probably best applied in 
combination with sequential deletions, are exciting and avenues for developing new and 
minimal baculoviral genomes that can be customized for optimal properties the laboratory 
and also in industrial manufacturing. 
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4/ Outlook 
Since the pioneering first reports more than three decades ago, the baculovirus / insect cell 
expression system  has developed into a mainstream production platform  accelerating a wide 
range of research projects in academic and industrial laboratories. In the post-genomic era, 
multiprotein complexes have entered center stage as essential catalysts of cellular activity, 
and notably the MultiBac BEVS has contributed substantially to make hitherto inaccessible 
protein complexes available, to unlock their structure and mechanism at molecular detail. 
Moreover, BEVS has emerged as remarkably useful tool in the biotech and pharma sector, for 
the production of complex biologics in disease prevention and therapy. The development of 
this versatile expression tool is continuing unabated as it is set to benefit markedly from 
powerful new synthetic biology techniques that are becoming available. Fueled by these 
innovations, BEVS is excellently positioned to play a key and increasing role in the life 
sciences, in basic and applied research in the future.  Exciting times are ahead of us. 
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Figures Legends 
Figure 1. The MultiBac baculovirus / insect cell expression system. The MultiBac system  
is shown in a schematic view (left). MultiBac consist of an engineered baculovirus optim ized 
for protein complex production. The MultiBac baculoviral genome exists as a bacterial 
artificial chromosome (BAC) in E.coli cells. It contains two integration sites for foreign 
genes, by transposition  or, alternatively, by site-specific recombination mediated by the Cre 
enzyme. MultiBac further consists of an array of plasmids called Acceptors and Donors. 
MultiBac baculovirions (centre) are generated by transfection of the composite MultiBac 
BAC in insect cells. MultiBac is used for a wide variety of applications in basic and applied 
research and development (right). 
Figure 2. MultiBac Acceptor and Donor plasmids. A variety of entry plasmids to integrate 
heterologous genes into the MultiBac baculoviral genome have been created since the 
introduction of the system 2004, each with its own merits. Functional modules contained in 
the plasmids are denoted (bottom). All plasmids are compatible with each other and can be 
used in various combinations to generate recombinant MultiBac baculoviral genomes for 
multiprotein expression and/or multigene delivery. 
Figure 3: MultiBac expression platform at the EMBL Grenoble. The standard operating 
protocol (SOP) utilized to express proteins and their complexes by using MultiBac is 
illustrated. The entire process takes two weeks from generation of the composite MultiBac 
BAC (bacmid) to quantitative expression analysis. A MultiBac baculovirus variant called 
EMBacY is used, producing yellow fluorescent protein (YFP) to track virus performance and 
heterologous protein production. Protein production is monitored by Western blot (WB) or by 
gele electrophoresis (SDS-PAGE). Production virus is stored long-term in frozen aliquots of 
baculovirus in insect cells (BIICs). 
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Figure 4. OmniBac – Universal transfer plasmids for every BEVS.  (a) Acceptor plasmids 
pOmniBac1 and pOmniBac2 are shown schematically, elements are marked above (Fig. 2). 
These Acceptors can be combined with the MultiBac Donor plasmids by Cre-LoxP 
recombination. (b) OmniBac plasmids contain elements for homologous recombination and 
also Tn7 based transposition. Multigene constructions based on OmniBac plasmids can 
therefore access all available baculovirus genomes. Thus, with the same plasmids, composite 
baculovirus for preclinical studies as well as manufacturing can be produced efficiently.  
Figure 5. ComplexLink  technology. (a) The ComplexLink technology was created to 
produce multiprotein complexes from self-processing polyprotein constructs as shown here 
schematically. The polyprotein contains a TEV protease and a flouorescent protein at the N-
terminus and C-terminus, respectively. Polyproteins are processed during expression into the 
individual protein entities by the highly specific TEV protease. (b) Polyprotein expression 
plasmids pPBac, pKL-PBac and pOmni-PBac are shown. DNA modules are marked as above 
(c.f. Fig 2). (c) Schematic representation of a self-processing polyprotein before TEV-
mediated cleavage encoding for influenza polymerase. TEV stands for tobacco etch NIa 
protease, PA, PB1 and PB2 are subunits of the trimeric enzyme complex, CFP stands for 
cyan fluorescent protein. BstEII and RsrII are asymmetric restriction enzymes that can be 
used to cleave polyprotein expression plasmids for restriction / ligation-based heterologous 
gene integration. 
Figure 6. MultiBac complex structure gallery. Selected examples of recent high impact 
structures of MultiBac produced biological specimens are shown. Examples include cryo-EM 
architectures of COPI-Coated Vesicles (EMD-2084 to EMD-2088), the complete human 
APC/C complex with coactivator and substrate (EMD-2651 to EMD-2654) and the human 
core-TFIID complex (EMD-2229 to EMD-2231). Notable structures that were determined by 
X-ray crystallography (PDB identifiers are provided in in brackets) include influenza 
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polymerases A and B bound to the viral RNA promoter (PDB identifier 4WSA, 4WRT), 
human Argonaute Ago2 in complex with miR-20a RNA  (4F3T), the spliceosomal complex 
Brr2HR  / Prp8Jab1  (4KIT), human GABA(B)  receptor (PDB 4MQE), the dynein-2 motor 
bound to ADP (4RH7), the  mitotic checkpoint complex MCC (4AEZ) and the 
GluN1/GluN2B N-methyl-D-aspartate receptor (3QEL). Molecular illustrations were 
prepared with PyMOL (www.pymol.org) and Adobe Photoshop Version CS6.  
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Figures  
Figure 1. The MultiBac baculovirus / insect cell expression system.  
 
Figure 2. MultiBac Acceptor and Donor plasmids.  
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Figure 3: MultiBac expression platform at the EMBL Grenoble.  
 
 
 
Figure 4. OmniBac – Universal transfer plasmids for every BEVS.   
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Figure 5. ComplexLink  technology.  
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Figure 6. MultiBac complex structure gallery. 
 
 
